HTA135 Isatuximab for the Third-Line Treatment of Relapsing or Refractory Multiple Myeloma: Therapeutic Value Classification in Colombia
Abstract
Authors
C Castro B Patiño Escobar K Gálvez M Lombana M Nova P Rodriguez Ordonez S Londono G. Sánchez-Vanegas